<DOC>
	<DOCNO>NCT00153816</DOCNO>
	<brief_summary>Extensive experimental observational data suggest intake calcium vitamin D exert protective effect colorectal neoplasia . Building previous work , investigator investigate chemopreventive effect vitamin D large bowel , study whether calcium vitamin D effective calcium alone , confirm positive finding regard calcium . The goal study development chemopreventive combination reduce risk colorectal neoplasia sufficiently permit lengthen surveillance interval patient clarify important issue regard mechanism colorectal carcinogenesis chemoprevention .</brief_summary>
	<brief_title>Vitamin D/Calcium Polyp Prevention Study</brief_title>
	<detailed_description>This study double-blind , placebo-controlled trial vitamin D and/or calcium supplementation prevention large bowel adenoma . Subjects recruit 11 Study Centers North America . Eligible subject least one large bowel adenoma remove 4 month prior study entry remain polyp bowel complete colonoscopic examination . Participants randomize partial 2 x 2 factorial design vitamin D ( 1000 IU/day ) , calcium carbonate ( 1200 mg elemental calcium/day ) , agent , placebo ( Full Factorial randomization ) . Women decline forego calcium supplementation randomize calcium alone calcium plus vitamin D ( Two Arm randomization ) . Randomization stratify gender , study center recruitment , anticipate follow-up interval ( see ) , conduct separately female subject randomize vitamin D. We anticipate enrol 3000 participant reach total 2400 randomized subject . As safety measure , blood level calcium , creatinine , 25- ( OH ) -vitamin D obtain baseline 1 year randomization , well 3 year randomization subject 5-year surveillance cycle . Every six month randomization subject complete questionnaire regard compliance study agent , use medication vitamin/mineral supplement , illness , hospitalization , dietary intake calcium vitamin D. The primary endpoint study new adenomas detect follow-up colonoscopy . These examination schedule occur either 3 year 5 year qualify examination , depend follow-up interval recommend patient 's endoscopist . Some patient may , medical reason , colonoscopy time 3 5 year qualify examination . Information exam include analysis appropriate . In primary analysis , occurrence new adenoma interval randomization follow-up exam compare subject randomize vitamin D ( without calcium ) versus randomize vitamin D ( without calcium ) , subject randomized calcium ( without vitamin D ) versus randomize calcium ( without vitamin D ; exclude woman elect receive calcium therefore participate calcium component study ) , randomized calcium plus vitamin D versus randomize calcium alone . In secondary analysis , examine impact baseline vitamin D level vitamin D receptor ( VDR ) polymorphisms vitamin D effect . Effects advance adenoma also assess secondary outcome . Participants invited participate optional Observational Follow Up phase study begin follow end treatment . In phase study , subject continue follow observational basis ( study treatment ) annual questionnaire time subsequent colonoscopy least three year follow colonoscopy study treatment end . We examine occurrence new adenoma interval colonoscopy exam end study treatment exam end observational follow period .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>One histologically verify neoplastic polyp ( adenoma ) least 2 mm size remove large bowel entire large bowel examine colonoscopy document free polyp area suspicious neoplasia within 120 day study entry Anticipated colonoscopic followup three year five year qualify colonoscopy Age 45 75 year enrollment ( Women ) Agreement avoid pregnancy ( i.e. , use standard contraception ) Willingness forego calcium supplementation ( include multivitamin contain calcium ) , woman , option take calcium supplementation 1200 mg/daily ( contain study pill ) Willingness forego vitamin D supplementation ( include multivitamin contain vitamin D ) Agreement daily dietary intake equivalent 1200 mg calcium Agreement daily dietary intake equivalent 400 IU vitamin D Blood calcium level within normal range Blood creatinine level exceed 20 % upper limit normal Serum 25 ( OH ) vitamin D within low limit normal 70 ng/ml Ability willingness follow study protocol , indicated provision inform consent participate Good general health , severely debilitate disease active malignancy might compromise patient 's ability complete study General exclusionary criterion : Participation another colorectal ( bowel ) study ( intervention study ) past 5 year Current participation clinical trial ( intervention study ) Pregnancy lactation A diagnosis narcotic alcohol dependence past 5 year A diagnosis dementia ( e.g . Alzheimer 's ) past 5 year A diagnosis significant psychiatric disability ( e.g . Schizophrenia , refractory bipolar disorder , current severe depression ) past 5 year Exclusions due derangement calcium metabolism indication /contraindications study agent : Any diagnosis kidney stone A diagnosis granulomatous disease , e.g . sarcoidosis , active chronic fungal mycobacterial infection ( tuberculosis , histoplasmosis , coccidioidomycosis , blastomycosis ) , berylliosis , Wegener 's granulomatosis past 5 year A diagnosis hyperparathyroidism serious disturbance calcium metabolism past 5 year A diagnosis severe kidney disease , e.g . chronic renal failure past 5 year A diagnosis unexplained hypercalcemia past 5 year Any Diagnosis osteoporosis physician recommendation treatment low bone mass A diagnosis two low trauma fracture past 5 year A diagnosis medical condition require treatment vitamin D ( e.g . osteomalacia ) past 5 year Exclusions due intestinal bowel problem : Any diagnosis invasive carcinoma large bowel ( even confine polyp ) Any diagnosis familial colorectal cancer syndrome , e.g . Familial Adenomatous Polyposis ( FAP ) ( include Gardner syndrome , Turcot 's syndrome ) , Hereditary Nonpolyposis Colorectal Cancer ( HNPCC ) , Hamartomatous Polyposis syndrome ( include PeutzJeghers Familial Juvenile Polyposis ) Any diagnosis inflammatory bowel disease , e.g . Crohn 's Disease , Ulcerative Colitis A diagnosis chronic intestinal malabsorption syndrome , e.g . celiac sprue , bacterial overgrowth , chronic pancreatitis , pancreatic insufficiency past 5 year Any large bowel resection Exclusions due poor health : A diagnosis malignancy , nonmelanoma skin cancer past 5 year A diagnosis severe lung disease class 3 4 ( e.g . chronic obstructive pulmonary disease emphysema require oxygen ) past 5 year A diagnosis severe heart disease : cardiovascular disease functional class 3 4 past 5 year Any diagnosis severe liver disease , e.g . cirrhosis Exclusions due ship regulation : Any current/past HIV positive diagnosis Active hepatitis B , define : Hep B surface antigen positive Active hepatitis C , define : measurable hepatitis C RNA Drug exclusion : Use chronic oral corticosteroid therapy past 5 year Use lithium past 5 year Use phenytoin 's past 5 year Use quinidine past 5 year Use therapeutic vitamin D past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Adenomatous polyp</keyword>
</DOC>